The omicron variant of SARS-CoV-2 infected very large numbers of SARS-CoV-2 vaccinated and convalescent individuals 1–3.
Pfizer is close to submitting data to the Food and Drug Administration on a fourth dose of its Covid-19 vaccine, according to CEO Albert Bourla.
The BA.2 sub-lineage of the Omicron variant now makes up nearly a quarter of new COVID-19 infections nationwide, the Centers for Disease Control and Prevention estimated Tuesday, up from around 1 in 10 new cases just a week prior.
Pfizer and BioNTech on Tuesday launched a clinical trial to evaluate the safety and effectiveness of a vaccine that targets the Covid omicron variant, as concerns grow that the current shots aren’t holding up against infections and mild illness caused by the strain discovered just over two months ago
ViiV Healthcare Reports Positive Phase III Study Results Of Investigational, Long-Acting, Injectable HIV-treatment Regimen Administered Every Two Months